726,373 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Bought by Western Standard LLC

Western Standard LLC purchased a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 726,373 shares of the medical technology company's stock, valued at approximately $6,668,000. Alphatec makes up 4.4% of Western Standard LLC's investment portfolio, making the stock its 9th biggest holding. Western Standard LLC owned 0.51% of Alphatec as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of ATEC. Royal Bank of Canada grew its stake in shares of Alphatec by 171.2% in the fourth quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock worth $29,240,000 after purchasing an additional 2,010,806 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Alphatec by 36.5% in the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after purchasing an additional 1,334,780 shares in the last quarter. Nuveen Asset Management LLC grew its stake in shares of Alphatec by 78.4% in the fourth quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after purchasing an additional 1,136,330 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Alphatec by 139.2% in the fourth quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock worth $16,278,000 after purchasing an additional 1,032,070 shares in the last quarter. Finally, Emerald Advisers LLC grew its stake in shares of Alphatec by 112.4% in the fourth quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock worth $13,366,000 after purchasing an additional 770,586 shares in the last quarter. Institutional investors own 66.35% of the company's stock.

Alphatec Stock Up 0.5%

Shares of Alphatec stock opened at $13.03 on Tuesday. The stock has a 50-day moving average price of $10.80 and a 200 day moving average price of $10.44. The company has a market cap of $1.90 billion, a P/E ratio of -10.18 and a beta of 1.06. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $13.07.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The business had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm's revenue was up 22.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Transactions at Alphatec

In related news, EVP David Sponsel sold 33,732 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the transaction, the executive vice president now directly owns 668,977 shares of the company's stock, valued at approximately $7,245,020.91. This trade represents a 4.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Scott Lish sold 23,183 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $12.03, for a total value of $278,891.49. Following the completion of the transaction, the chief operating officer now directly owns 844,494 shares in the company, valued at $10,159,262.82. The trade was a 2.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 126,945 shares of company stock valued at $1,416,352 in the last three months. Corporate insiders own 20.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ATEC. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Finally, Barclays raised their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Alphatec has an average rating of "Moderate Buy" and an average target price of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.